Skip to content

CAPA-VU Trial Catheter Ablation in Paroxymal Atrial Fibrillation Based on UNIVU

CAPA-VU Trial Catheter Ablation in Paroxymal Atrial Fibrillation Based on UNIVU

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03198858
Acronym
CAPA-VU
Enrollment
100
Registered
2017-06-26
Start date
2016-04-30
Completion date
2019-03-31
Last updated
2019-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Paroxysmal Atrial Fibrillation

Keywords

Paroxysmal Atrial Fibrillation

Brief summary

CartoUnivu™ module easily integrates into the workflow of PVI with the endpoint of unexcitability of the ablation line without prolonging the procedure time. It is associated with a marked reduction in fluoroscopic dose when compared to a conventional 3D-mapping system. The aim of this prospective randomized study is to evaluate during pulmonary vein isolation (PVI) for paroxysmal atrial fibrillation (PAF) whether the use of the IIM is: 1. feasible, 2. can help to reduce fluoroscopy time and burden and 3. has an influence on the procedure duration. Study design Prospective, randomized controlled multicenter trial, open label. Randomization 1:1

Detailed description

Catheter ablation (CA) has been established as a standard treatment especially in the setting of symptomatic paroxysmal atrial fibrillation (PAF) by means of pulmonary vein isolation (PVI) as recommended in the current guidelines. However, limitations regarding the success rate but also the x-ray burden with regard to patient and operator remain. One of the fundamental disadvantages of CA as it is routinely performed today, based on sequential application of radiofrequency current (RFC), is the need to verify the catheter position throughout the procedure by using fluoroscopy. Catheter guidance in the left atrium has been facilitated by the introduction of three-dimensional mapping systems allowing catheter localization by either weak magnetic or electrical fields with a consecutive reduction of fluoroscopy burden. Nevertheless, despite these 3D mapping systems the fluoroscopy exposure to patient and particularly electrophysiologists is considerable over time. Potential complications associated with radiation exposure include acute and subacute skin injury as well as radiation-induced cancer and genetic abnormalities. Recently, a new image integration module (IIM, CartoUnivu™ Module) has been introduced allowing the combination and integration of fluoroscopic images within the 3D electroanatomic map. Thus, an accurate navigation without the use of fluoroscopy after acquisition of a left atrial (LA) angiography is possible throughout the procedure. This implies the generation of the 3D left atrial map and catheter navigation for mapping and ablation. The potential benefit of the new image integration module has been showing the recent pilot study. The procedural endpoint is the unexcitability of the ablation line after isolation of the pulmonary veins, as described in detail previously. Catheter manipulation should be guided by 3D mapping if safe and feasible to minimize fluoroscopy time in both groups.

Interventions

PROCEDURECartoUnivu™

Ablation with Carto® 3 System and image integration module = IIM, CartoUnivu™

PROCEDUREAblation with Carto® 3 System

usual Pulmonary vein isolation Ablation with Carto® 3 System only

Sponsors

Biosense Webster, Inc.
CollaboratorINDUSTRY
Universitätsklinikum Hamburg-Eppendorf
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Masking description

Open Label

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years * Written informed consent * Symptomatic Paroxysmal Atrial Fibrillation with indication for ablation

Exclusion criteria

* Age \< 18 years * Persistent or Permanent Atrial Fibrillation (failed Cardioversion or episode duration \> 12 months) * Previous surgical or interventional therapy of atrial fibrillation * BMI \> 30 * Pregnant women or women of childbearing potential without a negative pregnancy test within 48 hours prior to treatment * History of hemorrhagic diathesis or other coagulopathies * Contraindications for oral anticoagulation * Hyper- or hypothyroidism * Has any condition that would make participation not be in the best interest of the subject

Design outcomes

Primary

MeasureTime frameDescription
Radiation duration1 year follow upReduction of radiation duration during ablation

Secondary

MeasureTime frameDescription
procedure duration1 year follow upReduction of procedure duration during ablation

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026